Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2012 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | http://repositorio.unifesp.br/handle/11600/34357 http://dx.doi.org/10.1128/CVI.05414-11 |
Resumo: | Vaccination with peptide 10 (P10), derived from the Paracoccidioides brasiliensis glycoprotein 43 (gp43), induces a Th1 response that protects mice in an intratracheal P. brasiliensis infection model. Combining P10 with complete Freund's adjuvant (CFA) or other adjuvants further increases the peptide's antifungal effect. Since dendritic cells (DCs) are up to 1,000-fold more efficient at activating T cells than CFA, we examined the impact of P10-primed bone-marrow-derived DC vaccination in mice. Splenocytes from mice immunized with P10 were stimulated in vitro with P10 or P10-primed DCs. T cell proliferation was significantly increased in the presence of P10-primed DCs compared to the peptide. the protective efficacy of P10-primed DCs was studied in an intratracheal P. brasiliensis model in BALB/c mice. Administration of P10-primed DCs prior to (via subcutaneous vaccination) or weeks after (via either subcutaneous or intravenous injection) P. brasiliensis infection decreased pulmonary damage and significantly reduced fungal burdens. the protective response mediated by the injection of primed DCs was characterized mainly by an increased production of gamma interferon (IFN-gamma) and interleukin 12 (IL-12) and a reduction in IL-10 and IL-4 compared to those of infected mice that received saline or unprimed DCs. Hence, our data demonstrate the potential of P10-primed DCs as a vaccine capable of both the rapid protection against the development of serious paracoccidioidomycosis or the treatment of established P. brasiliensis disease. |
id |
UFSP_5c73a890e7ad72d2e9d5ecd0fad26ec1 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br:11600/34357 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
Magalhaes, A.Ferreira, K. S. [UNIFESP]Almeida, S. R.Nosanchuk, J. D.Travassos, L. R. [UNIFESP]Taborda, Carlos Pelleschi [UNIFESP]Universidade de São Paulo (USP)Universidade Federal de São Paulo (UNIFESP)Albert Einstein Coll Med2016-01-24T14:17:36Z2016-01-24T14:17:36Z2012-01-01Clinical and Vaccine Immunology. Washington: Amer Soc Microbiology, v. 19, n. 1, p. 23-29, 2012.1556-6811http://repositorio.unifesp.br/handle/11600/34357http://dx.doi.org/10.1128/CVI.05414-11WOS000298675000005.pdf10.1128/CVI.05414-11WOS:000298675000005Vaccination with peptide 10 (P10), derived from the Paracoccidioides brasiliensis glycoprotein 43 (gp43), induces a Th1 response that protects mice in an intratracheal P. brasiliensis infection model. Combining P10 with complete Freund's adjuvant (CFA) or other adjuvants further increases the peptide's antifungal effect. Since dendritic cells (DCs) are up to 1,000-fold more efficient at activating T cells than CFA, we examined the impact of P10-primed bone-marrow-derived DC vaccination in mice. Splenocytes from mice immunized with P10 were stimulated in vitro with P10 or P10-primed DCs. T cell proliferation was significantly increased in the presence of P10-primed DCs compared to the peptide. the protective efficacy of P10-primed DCs was studied in an intratracheal P. brasiliensis model in BALB/c mice. Administration of P10-primed DCs prior to (via subcutaneous vaccination) or weeks after (via either subcutaneous or intravenous injection) P. brasiliensis infection decreased pulmonary damage and significantly reduced fungal burdens. the protective response mediated by the injection of primed DCs was characterized mainly by an increased production of gamma interferon (IFN-gamma) and interleukin 12 (IL-12) and a reduction in IL-10 and IL-4 compared to those of infected mice that received saline or unprimed DCs. Hence, our data demonstrate the potential of P10-primed DCs as a vaccine capable of both the rapid protection against the development of serious paracoccidioidomycosis or the treatment of established P. brasiliensis disease.Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Univ São Paulo, Inst Biomed Sci, Dept Microbiol, São Paulo, BrazilUniv São Paulo, Lab Med Mycol IMT SP LIM53, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Biol Sci, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, São Paulo, BrazilUniv São Paulo, Dept Clin & Toxicol Anal, Fac Pharmaceut Sci, São Paulo, BrazilAlbert Einstein Coll Med, Dept Med, Bronx, NY 10467 USAAlbert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10467 USAUniversidade Federal de São Paulo, Dept Biol Sci, São Paulo, BrazilUniversidade Federal de São Paulo, Dept Microbiol Immunol & Parasitol, São Paulo, BrazilFAPESP: 2009/15823-7FAPESP: 2010/51423-0CNPq: 470513/2009-8Web of Science23-29engAmer Soc MicrobiologyClinical and Vaccine ImmunologyProphylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESPORIGINALWOS000298675000005.pdfapplication/pdf1479089${dspace.ui.url}/bitstream/11600/34357/1/WOS000298675000005.pdfccb37c2ef1360d82dfd37a5863e2f4d1MD51open accessTEXTWOS000298675000005.pdf.txtWOS000298675000005.pdf.txtExtracted texttext/plain36576${dspace.ui.url}/bitstream/11600/34357/2/WOS000298675000005.pdf.txt6d206fcc9c80d1cb256379d8531bdb37MD52open access11600/343572022-09-27 09:48:30.141open accessoai:repositorio.unifesp.br:11600/34357Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:23:19.376696Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.en.fl_str_mv |
Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis |
title |
Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis |
spellingShingle |
Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis Magalhaes, A. |
title_short |
Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis |
title_full |
Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis |
title_fullStr |
Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis |
title_full_unstemmed |
Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis |
title_sort |
Prophylactic and Therapeutic Vaccination Using Dendritic Cells Primed with Peptide 10 Derived from the 43-Kilodalton Glycoprotein of Paracoccidioides brasiliensis |
author |
Magalhaes, A. |
author_facet |
Magalhaes, A. Ferreira, K. S. [UNIFESP] Almeida, S. R. Nosanchuk, J. D. Travassos, L. R. [UNIFESP] Taborda, Carlos Pelleschi [UNIFESP] |
author_role |
author |
author2 |
Ferreira, K. S. [UNIFESP] Almeida, S. R. Nosanchuk, J. D. Travassos, L. R. [UNIFESP] Taborda, Carlos Pelleschi [UNIFESP] |
author2_role |
author author author author author |
dc.contributor.institution.none.fl_str_mv |
Universidade de São Paulo (USP) Universidade Federal de São Paulo (UNIFESP) Albert Einstein Coll Med |
dc.contributor.author.fl_str_mv |
Magalhaes, A. Ferreira, K. S. [UNIFESP] Almeida, S. R. Nosanchuk, J. D. Travassos, L. R. [UNIFESP] Taborda, Carlos Pelleschi [UNIFESP] |
description |
Vaccination with peptide 10 (P10), derived from the Paracoccidioides brasiliensis glycoprotein 43 (gp43), induces a Th1 response that protects mice in an intratracheal P. brasiliensis infection model. Combining P10 with complete Freund's adjuvant (CFA) or other adjuvants further increases the peptide's antifungal effect. Since dendritic cells (DCs) are up to 1,000-fold more efficient at activating T cells than CFA, we examined the impact of P10-primed bone-marrow-derived DC vaccination in mice. Splenocytes from mice immunized with P10 were stimulated in vitro with P10 or P10-primed DCs. T cell proliferation was significantly increased in the presence of P10-primed DCs compared to the peptide. the protective efficacy of P10-primed DCs was studied in an intratracheal P. brasiliensis model in BALB/c mice. Administration of P10-primed DCs prior to (via subcutaneous vaccination) or weeks after (via either subcutaneous or intravenous injection) P. brasiliensis infection decreased pulmonary damage and significantly reduced fungal burdens. the protective response mediated by the injection of primed DCs was characterized mainly by an increased production of gamma interferon (IFN-gamma) and interleukin 12 (IL-12) and a reduction in IL-10 and IL-4 compared to those of infected mice that received saline or unprimed DCs. Hence, our data demonstrate the potential of P10-primed DCs as a vaccine capable of both the rapid protection against the development of serious paracoccidioidomycosis or the treatment of established P. brasiliensis disease. |
publishDate |
2012 |
dc.date.issued.fl_str_mv |
2012-01-01 |
dc.date.accessioned.fl_str_mv |
2016-01-24T14:17:36Z |
dc.date.available.fl_str_mv |
2016-01-24T14:17:36Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.citation.fl_str_mv |
Clinical and Vaccine Immunology. Washington: Amer Soc Microbiology, v. 19, n. 1, p. 23-29, 2012. |
dc.identifier.uri.fl_str_mv |
http://repositorio.unifesp.br/handle/11600/34357 http://dx.doi.org/10.1128/CVI.05414-11 |
dc.identifier.issn.none.fl_str_mv |
1556-6811 |
dc.identifier.file.none.fl_str_mv |
WOS000298675000005.pdf |
dc.identifier.doi.none.fl_str_mv |
10.1128/CVI.05414-11 |
dc.identifier.wos.none.fl_str_mv |
WOS:000298675000005 |
identifier_str_mv |
Clinical and Vaccine Immunology. Washington: Amer Soc Microbiology, v. 19, n. 1, p. 23-29, 2012. 1556-6811 WOS000298675000005.pdf 10.1128/CVI.05414-11 WOS:000298675000005 |
url |
http://repositorio.unifesp.br/handle/11600/34357 http://dx.doi.org/10.1128/CVI.05414-11 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Clinical and Vaccine Immunology |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
23-29 |
dc.publisher.none.fl_str_mv |
Amer Soc Microbiology |
publisher.none.fl_str_mv |
Amer Soc Microbiology |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
bitstream.url.fl_str_mv |
${dspace.ui.url}/bitstream/11600/34357/1/WOS000298675000005.pdf ${dspace.ui.url}/bitstream/11600/34357/2/WOS000298675000005.pdf.txt |
bitstream.checksum.fl_str_mv |
ccb37c2ef1360d82dfd37a5863e2f4d1 6d206fcc9c80d1cb256379d8531bdb37 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
|
_version_ |
1783460284620341248 |